NYSEMKT: CPHIChina Pharma Holdings Inc Stock
$0.32-0.01 (-3.03%)
Updated Apr 19, 2024
CPHI Price
$0.32
Fair Value Price
N/A
Market Cap
$4.71M
52 Week Low
$0.30
52 Week High
$2.70
P/E
-0.35x
P/B
0.63x
P/S
0.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.01M
Earnings
-$3.08M
Gross Margin
-4%
Operating Margin
-39.15%
Profit Margin
-43.9%
Debt to Equity
1.21
Operating Cash Flow
-$700k
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CPHI Overview
China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Haikou, Hainan and currently employs 397 full-time employees. The firm conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People's Republic of China (PRC). The company is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. The company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The firm manufactured over 20 pharmaceutical products for various diseases and medical indications. The company offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CPHI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CPHI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CPHI is good value based on its book value relative to its share price (0.63x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.03x)
P/B vs Industry Valuation
CPHI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CPHI due diligence checks available for Premium users.
Be the first to know about important CPHI news, forecast changes, insider trades & much more!
CPHI News
Valuation
CPHI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
46.11x
Market
40.51x
CPHI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
2.03x
CPHI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CPHI's financial health
Profit margin
Revenue
$2.1M
Net Income
-$1.2M
Profit Margin
-57.3%
CPHI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CPHI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.5M
Liabilities
$9.0M
Debt to equity
1.21
CPHI's short-term liabilities ($6.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CPHI's short-term assets ($6.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CPHI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CPHI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.3k
Investing
-$4.5k
Financing
$30.4k
CPHI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CPHI vs Pharmaceutical Stocks
China Pharma Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.